Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
Advanced Renal Cell Carcinoma
Advertisement
Latest News
Drs. Beckermann and Braun reflect on key lessons from the trial, emphasizing the importance of prioritizing driver mutations.
Drs. Beckermann and Braun break down the selection process for neoantigens in the trial for personalized RCC vaccines.
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
The combination therapy provided similar survival rates and toxicity in an older patient population.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Shore highlights post hoc analyses of ultra-low PSA responses and their correlation with outcomes in the ARANOTE study.
Results of the CREST study show that sasanlimab plus BCG improves EFS compared with BCG alone in high-risk NMIBC.
Drs. Chang and Joyce consider the role that N-803 now plays within the treatment paradigm for BCG-unresponsive bladder CIS.
Drs. Chang, Joyce take a look at QUILT-3.032, including complete responses to N-803 plus BCG in BCG-unresponsive bladder CIS.
Dr. Daneshmand discusses some of the designs and results of ADVANCED-2, PIVOT-006, ABLE-22, and more.
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.